Botox promotions investigated.
by Ault, Alicia
The U.S. Attorney's office for the northern district of
Georgia has subpoenaed Allergan, seeking documents that might show
off-label promotion of Botox (botulinum toxin type A) for the treatment
of headache. The company confirmed the inquiry in a statement, and said
that while Allergan currently has Botox in phase III studies for
headache, "it is Allergan's policy to promote its products
only in a manner consistent with the FDA-approved product
labeling." Allergan also intends to comply "with all
applicable laws, rules, and regulations," according to the
statement. Botox is Allergan's second-biggest-selling product, with
$1.2 billion in sales in 2007. The company is projecting sales of about
$1.3 billion this year.
COPYRIGHT 2008 International Medical News
Group Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
Copyright 2008 Gale, Cengage Learning. All rights
reserved. Gale Group is a Thomson Corporation Company.
NOTE: All illustrations and photos have been removed from this article.